Multipotentiality of Luliconazole against Various Fungal Strains: Novel Topical Formulations and Patent Review

Ayushi       Mahajan; Lakhvir       Kaur; Gurjeet       Singh; Ravi    Kumar   Dhawan; Lovepreet       Singh

doi:10.2174/2772434416666211111105854

Abstract

Luliconazole is a broad-spectrum antifungal agent with impactful fungicidal and fungistatic activity. It has shown exceptional potency against miscellaneous fungal strains like Candida, Aspergillus, Malassezia, Fusarium species and various dermatophytes. Luliconazole belongs to class II of the Biopharmaceutical Classification System with low aqueous solubility. Although it is available conventionally as 1% w/v topical cream, it has limitations of lower skin permeation and shorter skin retention. Therefore, nanoformulations based on various polymers and nanostructure carriers can be employed to overcome the impediments regarding topical delivery and efficacy of luliconazole. In this review, we have tried to provide insight into the literature gathered from authentic web resources and research articles regarding recent research conducted on the subject of formulation development, patents, and future research requisites of luliconazole. Nanoformulations can play a fundamental role in improving topical delivery by escalating dermal localization and skin penetration. Fabricating luliconazole into nanoformulations can overcome the drawbacks and can efficiently enhance its antimycotic activity. It has been concluded that luliconazole has exceptional potential in the treatment of various fungal infections, and therefore, it should be exploited to its maximum for its innovative application in the field of mycology.

Keywords: Luliconazole, antifungal, nanoformulations, topical, fungi, mycology.

« Previous Next »

Graphical Abstract

[1] 
Baddley JW, Winthrop KL, Patkar NM, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis  2011; 17(9): 1664-9.
[http://dx.doi.org/10.3201/eid1709.101987] [PMID: 21888792] 
[2] 
Schwartz RA. Superficial fungal infections. Lancet  2004; 364(9440): 1173-82.
[http://dx.doi.org/10.1016/S0140-6736(04)17107-9] [PMID: 15451228] 
[3] 
Kirk PM, Cannon PF, Minter DW, Stalpers JA. Dictionary of the fungi.  10th ed. Wallingford, UK: CAB International 2008.
[4] 
Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol  2017; 1508: 17-65.
[http://dx.doi.org/10.1007/978-1-4939-6515-1_2] [PMID: 27837497] 
[5] 
Shakeel F, Haq N, Elbadry M, Alanazi F. Ultra fine super selfnanoemulsifying drug delivery system (SNEDDS) enhanced solubility and dissolution of indomethacin. J Mol Liq  2013; 180: 89-94.
[http://dx.doi.org/10.1016/j.molliq.2013.01.008] 
[6] 
Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol  2015; 81(5): 457-63.
[http://dx.doi.org/10.4103/0378-6323.162328] [PMID: 26261140] 
[7] 
Moslem M, Mahmoudabadi AZ. The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains. Iran J Microbiol  2020; 12(2): 170-6.
[PMID: 32494352] 
[8] 
Kaur M, Singh K, Jain SK. Luliconazole vesicular based gel formulations for its enhanced topical delivery. J Liposome Res  2020; 30(4): 388-406.
[http://dx.doi.org/10.1080/08982104.2019.1682602] [PMID: 31631734] 
[9] 
Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses  2007; 50(1): 35-40.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01305.x] [PMID: 17302746] 
[10] 
Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid  2014; 9: 113-24.
[http://dx.doi.org/10.2147/CE.S49629] [PMID: 25285056] 
[11] 
Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother  2004; 10(4): 216-9.
[http://dx.doi.org/10.1007/s10156-004-0327-1] [PMID: 15365862] 
[12] 
National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 3003141, Luliconazole. 2004. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Luliconazole
[13] 
Patel HM, Gangat A, Patel UB, Akbari B. Fabrication and characterization of luliconazole film-forming topical spray for the treatment of fungal infections. MJPS  2020; 6(2): 52-64.
[http://dx.doi.org/10.1016/j.heliyon.2019.e01688] 
[14] 
Kumar M, Shanthi N, Mahato AK, Soni S, Rajnikanth PS. Preparation of luliconazole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity. Heliyon  2019; 5(5): e01688.
[http://dx.doi.org/10.1016/j.heliyon.2019.e01688] [PMID: 31193099] 
[15] 
Zheng C, Wang Z, Wang Q. Efficient preparation of the chiral intermediate of luliconazole with Lactobacillus kefir alcohol dehydrogenase through rational rearrangement of the substrate binding pocket. Mol Catal  2021; 509: 111639.
[http://dx.doi.org/10.1016/j.mcat.2021.111639] 
[16] 
Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia  2008; 166(5-6): 353-67.
[http://dx.doi.org/10.1007/s11046-008-9109-0] [PMID: 18478357] 
[17] 
Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ  2012; 345: e4380.
[http://dx.doi.org/10.1136/bmj.e4380] [PMID: 22782730] 
[18] 
Jones TM, Jarratt MT, Mendez-Moguel I, et al. A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥ 12 years with tinea cruris. J Drugs Dermatol  2014; 13(1): 32-8.
[PMID: 24385117] 
[19] 
Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol  2013; 58(1): 34-8.
[http://dx.doi.org/10.4103/0019-5154.105284] [PMID: 23372210] 
[20] 
Jarratt M, Jones T, Kempers S, et al. Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study. Cutis  2013; 91(4): 203-10.
[PMID: 23763082] 
[21] 
Lakshmi VC, Bengalorkar GM, Shiva Kumar V. Clinical efficacy of topical terbinafine versus topical luliconazole in treatment of tinea corporis/tinea cruris patients. Br J Pharm Res  2013; 3: 1001-14.
[http://dx.doi.org/10.9734/BJPR/2013/4348] 
[22] 
Baghi N, Shokohi T, Badali H, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol  2016; 54(7): 757-63.
[http://dx.doi.org/10.1093/mmy/myw016] [PMID: 27118804] 
[23] 
Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A. Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis. Antimicrob Agents Chemother  2014; 58(6): 3553-5.
[http://dx.doi.org/10.1128/AAC.02706-13] [PMID: 24709260] 
[24] 
Gnat S, Dyląg M, Łagowski D, Zielinski J. Therapeutic efficacy of topically used luliconazole vs. terbinafine 1% creams. Mycoses  2021; 64(8): 967-75.
[http://dx.doi.org/10.1111/myc.13289] [PMID: 33884673] 
[25] 
Nakamura A, Hirakawa S, Nagai H, Inagaki K. A comparative study between two antifungal agents, luliconazole and efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model. Med Mycol  2021; 59(3): 289-95.
[http://dx.doi.org/10.1093/mmy/myaa111] [PMID: 33539539] 
[26] 
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis  2016; 62(4): e1-e50.
[http://dx.doi.org/10.1093/cid/civ933] [PMID: 26679628] 
[27] 
Taghipour S, Kiasat N, Shafiei S, Halvaeezadeh M, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A. Luliconazole, a new antifungal against Candida species isolated from different sources. J Mycol Med  2018; 28(2): 374-8.
[http://dx.doi.org/10.1016/j.mycmed.2017.11.004] [PMID: 29198426] 
[28] 
Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother  2006; 12(3): 163-5.
[http://dx.doi.org/10.1007/s10156-006-0440-4] [PMID: 16826352] 
[29] 
Niwano Y, Kuzuhara N, Goto Y, et al. Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. Int J Antimicrob Agents  1999; 12(3): 221-8.
[http://dx.doi.org/10.1016/S0924-8579(99)00076-X] [PMID: 10461840] 
[30] 
Shokoohi G, Rouhi R, Etehadnezhad M. In vitro antifungal activity of luliconazole, efinaconazole, and nine comparators against Aspergillus and Candida strains isolated from otomycosis. Jundishapur J Microbiol  2021; 14(4): 3.
[http://dx.doi.org/10.5812/jjm.115902] 
[31] 
Hivary S, Fatahinia M, Halvaeezadeh M, Mahmoudabadi AZ. The potency of luliconazole against clinical and environmental Aspergillus nigri complex. Iran J Microbiol  2019; 11(6): 510-9.
[PMID: 32148683] 
[32] 
Zargaran M, Taghipour S, Kiasat N, et al. Luliconazole, an alternative antifungal agent against Aspergillus terreus. J Mycol Med  2017; 27(3): 351-6.
[http://dx.doi.org/10.1016/j.mycmed.2017.04.011] [PMID: 28483449] 
[33] 
Abastabar M, Rahimi N, Meis JF, et al. Potent activities of novel imidazoles lanoconazole and luliconazole against a collection of azole-resistant and -susceptible Aspergillus fumigatus strains. Antimicrob Agents Chemother  2016; 60(11): 6916-9.
[http://dx.doi.org/10.1128/AAC.01193-16] [PMID: 27572389] 
[34] 
Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. J Dermatol  2015; 42(3): 250-7.
[http://dx.doi.org/10.1111/1346-8138.12700] [PMID: 25736318] 
[35] 
Zisova LG. Malassezia species and seborrheic dermatitis. Folia Med (Plovdiv)  2009; 51(1): 23-33.
[PMID: 19437895] 
[36] 
Koga H, Munechika Y, Matsumoto H, et al. Guinea pig seborrheic dermatitis model of Malassezia restricta and the utility of luliconazole. Med Mycol  2020; 58(6): 820-6.
[http://dx.doi.org/10.1093/mmy/myz128] [PMID: 31873751] 
[37] 
Dabas Y, Bakhshi S, Xess I. Fatal cases of bloodstream infection by Fusarium solani and review of published literature. Mycopathologia  2016; 181(3-4): 291-6.
[http://dx.doi.org/10.1007/s11046-015-9960-8] [PMID: 26541869] 
[38] 
Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect  2004; 10(Suppl. 1): 67-75.
[http://dx.doi.org/10.1111/j.1470-9465.2004.00845.x] [PMID: 14748803] 
[39] 
Gharaghani M, Hivary S, Taghipour S, Zarei-Mahmoudabadi A. Luliconazole, a highly effective imidazole, against Fusarium species complexes. Med Microbiol Immunol (Berl)  2020; 209(5): 603-12.
[http://dx.doi.org/10.1007/s00430-020-00672-4] [PMID: 32253502] 
[40] 
Todokoro D, Suzuki T, Tamura T, et al. Efficacy of luliconazole against broad-range filamentous fungi including Fusarium solani species complex causing fungal keratitis. Cornea  2019; 38(2): 238-42.
[http://dx.doi.org/10.1097/ICO.0000000000001812] [PMID: 30422866] 
[41] 
Luliconazole. Drugbank.  Available from: https://go.drugbank.com/drugs/DB08933.
[42] 
Luliconazole (Rx). Medscape.  Available from: https://reference.medscape.com/drug/Luzu.
[43] 
Kansagra H, Mallick S. Microemulsion-based antifungal gel of luliconazole for dermatophyte infections: formulation, characterization and efficacy studies. Int J Pharm Investig  2016; 46: 21-8.
[http://dx.doi.org/10.1007/s40005-015-0209-9] 
[44] 
Sharma M, Mundlia J, Kumar T, Ahuja M. A novel microwave-assisted synthesis, characterization and evaluation of luliconazole-loaded solid lipid nanoparticles. Polym Bull  2021; 78: 2553-67.
[http://dx.doi.org/10.1007/s00289-020-03220-5] 
[45] 
Shaikh AN, Pawar AY. Formulation and evaluation nanosponges loaded hydrogel of luliconazole. Int J Sci Dev Res  2020; 5(8): 215-27.
[46] 
Mahmood A, Rapalli VK, Waghule T, Gorantla S, Singhvi G. Luliconazole loaded lyotropic liquid crystalline nanoparticles for topical delivery: QbD driven optimization, in-vitro characterization and dermatokinetic assessment. Chem Phys Lipids  2021; 234: 105028.
[http://dx.doi.org/10.1016/j.chemphyslip.2020.105028] [PMID: 33309940] 
[47] 
Shaikh MS, Kale MA, Shaikh M, Mahaparale PR. Formulation, characterization and antimicrobial studies of lyophilized luliconazole nanosuspension for enhancing solubility using modified polymer. Int J Polym Mater Polym Biomater  2021; 1-15. [Ahead of print].
[http://dx.doi.org/10.1080/00914037.2021.1879077] 
[48] 
Alhakamy NA, Al-Rabia MW, Md S, et al. Development and optimization of luliconazole spanlastics to augment the antifungal activity against Candida albicans. Pharmaceutics  2021; 13(7): 977.
[http://dx.doi.org/10.3390/pharmaceutics13070977] [PMID: 34203359] 
[49] 
Firdaus S, Hassan N, Mirza MA, et al. FbD directed fabrication and investigation of luliconazole based SLN gel for the amelioration of candidal vulvovaginitis: a 2 T (thermosensitive & transvaginal) approach. Saudi J Biol Sci  2021; 28(1): 317-26.
[http://dx.doi.org/10.1016/j.sjbs.2020.10.005] [PMID: 33424312] 
[50] 
Miki T, Nozawa A, Kubota N, Tomiyama S, Kobayashi H. External pharmaceutical composition comprising luliconazole and an alpha hydroxycarboxylic acid such as lactic acid, glycolic acid or malic acid. NZ571818A, 2006.
[51] 
Masuda T, Nishida N, Kobayashi N, Sasagawa H. Antifungal composition. EP2191827B1, 2008.
[52] 
Kaneda H, Koga H. Formulation for improving skin permeability of luliconazole. JP2012144449A, 2011.
[53] 
Kubota N, Kobayashi H, Masuda T. Antimycotic pharmaceutical composition. WO 2011155640A1, 2011.
[54] 
Yokoi Y, Abe A, Shimizu K, Osato D, Toru N. Pharmaceutical liquid composition. JP6503627B2, 2014.
[55] 
Vontz CG, Nakamura N, Porceri-Morton CD. Anti- fungal formulation containing luliconazole. EP2745692A1, 2014.
[56] 
Masuda T, Kobayashi H. Pharmaceutical composition containing luliconazole. WO2014042043A1, 2014.
[57] 
Tao J, Dejun J. A kind of luliconazole external spraying agent pharmaceutical composition and preparation method thereof. CN107865825A, 2016.
[58] 
Dhuppad RU, Bhamre NB, Gaikwad PS, Alai VR. Luliconazole stable topical compositions. WO2017203456A1, 2017.
[59] 
Mizutari Y, Matsumoto S. Topical composition containing luliconazole. JP6827092B2, 2019.
[60] 
Yanjun W, Hua W, Xiangda Y. Crystal formation of luliconazole and preparation method thereof. CN103012385B, 2012.
[61] 
Bhirud SB, Bhushan KH, Zhope SS. Process for preparation of luliconazole. WO2016092478A1, 2015.
[62] 
Masuda T, Kobayashi H. Method of evaluating pharmaceutical preparation containing luliconazole and index substance. US9085554B2, 2015.

Rights & Permissions Print Cite

Article Metrics

23

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/2772434416666211111105854	Print ISSN 2772-4344
Publisher Name Bentham Science Publisher	Online ISSN 2772-4352

Recent Advances in Anti-Infective Drug Discovery

Multipotentiality of Luliconazole against Various Fungal Strains: Novel Topical Formulations and Patent Review

Abstract

Graphical Abstract

Related Journals

Related Books